secwatch.observer — SEC 8-K summary
======================================

Issuer:     LISATA THERAPEUTICS, INC. (LSTA)
CIK:        0000320017
Form:       8-K
Filed at:   2023-08-14T23:59:59+00:00
Accession:  0000320017-23-000054
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lisata Q2 net loss $4.0M, extends cash runway to Q1 2026; tech transfer deal for TPN platform
--------------------------------------------------------------------------------

- Net loss $4.0M in Q2 2023 vs $6.6M in Q2 2022, down 40% due to $2.2M NJ tax credit.
- Cash and securities $57.6M; projected runway into Q1 2026 based on capital conservation measures.
- Signed technology transfer agreement for TPN platform with Impilo Therapeutics; receives equity stake, no future capital commitment.
- LSTA1 progress: ASCEND Phase 2b enrollment >70% target; BOLSTER trial open; iLSTA initiated in Australia.
- FDA granted orphan designation for LSTA1 in malignant glioma; GBM trial planned for Q4 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/320017/000032001723000054/0000320017-23-000054-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/320017/000032001723000054/clbs-20230814.htm
  HTML page:      https://secwatch.observer/filing/0000320017-23-000054

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer